17 September, 2026 — In a landmark legislative move that signals a fundamental shift in how the European Union approaches non-communicable diseases (NCDs), the European Parliament has officially adopted the Public Health Committee’s comprehensive report on cardiovascular health. This decision marks a pivotal moment in the implementation of the European Commission’s "Safe Hearts Plan," promising to move Europe away from siloed medical approaches toward a more integrated, patient-centered model of care.
For the European Respiratory Society (ERS) and the broader medical community, the adoption of this report is not merely a procedural victory; it is a long-awaited recognition that the heart and lungs do not function in isolation. By formally acknowledging the intrinsic links between cardiovascular and respiratory health, the Parliament has paved the way for a holistic framework that addresses the comorbidities that often devastate patient health outcomes.
The Core Mandate: Rethinking the NCD Strategy
The European Parliament’s report serves as the primary legislative response to the Commission’s Safe Hearts Plan. The core objective is to reduce the burden of cardiovascular disease (CVD), which remains a leading cause of mortality across the continent. However, the report distinguishes itself by emphasizing that effective CVD management is impossible without addressing the comorbid conditions that often accelerate cardiovascular decline.
Central to this new policy direction is the "cross-disease approach." For years, respiratory conditions like Chronic Obstructive Pulmonary Disease (COPD) and obstructive sleep apnoea were treated as distinct, separate entities from heart health. The new parliamentary mandate demands that these conditions be addressed in concert, recognizing that systemic inflammation, hypoxia, and shared risk factors (such as smoking, air pollution, and sedentary lifestyles) link these chronic diseases in a bidirectional relationship.
Key Pillars of the Adopted Report:
- Prioritizing Prevention: A shift in focus from late-stage intervention to early-life and mid-life preventative measures.
- Early Detection: Standardizing screening protocols to identify risks before they manifest as acute clinical events.
- Integrated Care Pathways: Mandating that health systems bridge the gap between cardiology and pulmonology departments.
- Addressing Health Inequalities: Ensuring that the Safe Hearts Plan is implemented equitably across all EU Member States, regardless of current healthcare infrastructure disparities.
Chronology: The Path to Integration
The journey to this week’s vote was characterized by years of advocacy, data collection, and intense debate within the European institutions.
- 2024: Initial Consultations. The European Commission initiates a series of stakeholder dialogues regarding the burden of NCDs, identifying heart health as a primary target for policy intervention.
- Early 2025: The Safe Hearts Plan. The Commission releases the formal Safe Hearts Plan draft, outlining the strategy to combat cardiovascular disease. While the plan was comprehensive, critics and public health bodies like the ERS noted a lack of explicit focus on respiratory comorbidities.
- Mid-2025: The Public Health Committee Review. The European Parliament’s Public Health Committee takes up the draft. Advocacy efforts from the ERS and the European Lung Foundation (ELF) intensify, highlighting how COPD patients face significantly higher risks of cardiac events.
- Early 2026: Evidence-Based Lobbying. During the EU Screening Week, the ERS holds high-profile testing events, demonstrating the feasibility of integrating lung function assessments into standard health check-ups.
- September 2026: The Plenary Vote. Following months of deliberation, the European Parliament formally adopts the report, incorporating the amendments that elevate the status of respiratory health within the cardiovascular strategy.
Supporting Data: The Case for Synergy
The impetus for this legislative change is rooted in sobering epidemiological data. The synergy between heart and lung health is not merely theoretical; it is a clinical reality that is reflected in European hospital admissions.
The Comorbidity Crisis
Studies cited during the parliamentary debates indicate that approximately 20% to 30% of patients with COPD also suffer from congestive heart failure. Conversely, heart failure patients frequently exhibit undiagnosed obstructive sleep apnoea, which significantly exacerbates their condition.
- Mortality Trends: Respiratory conditions remain a top-tier cause of death in the EU. When paired with cardiovascular disease, the five-year mortality rate for patients increases by nearly 40% compared to those with either condition alone.
- The Cost of Inaction: The economic burden of NCDs is staggering. Beyond the direct costs of emergency hospitalizations for exacerbations, the loss of productivity due to chronic respiratory-cardiovascular decline costs the EU economy tens of billions of euros annually.
- Detection Gaps: Current screening methods often miss the "early markers" of cross-condition deterioration. The ERS has demonstrated that by introducing simple respiratory function assessments—such as spirometry—into standard cardiac check-ups, physicians can identify at-risk patients up to three years earlier than traditional methods allow.
Official Responses: A United Front
The reception from the scientific and policy communities has been overwhelmingly positive, though stakeholders emphasize that the "real work" begins now.
The European Respiratory Society (ERS) Perspective
Raquel Duarte, the ERS Director of Scientific Affairs to the EU, has been a leading voice in these negotiations. Following the vote, she underscored the importance of the parliament’s shift in mindset.
"This vote by the European Parliament marks an important step towards strengthening cardiovascular and respiratory health together," Duarte stated. "The Safe Hearts Plan provides a valuable framework for addressing cardiovascular disease, and importantly its comorbidities and precursors across the entire health pathway—from prevention and early detection to treatment and rehabilitation."
Duarte emphasized that the focus on COPD and the reduction of risk factors is a victory for public health, but she remained cautious about the implementation phase. "The next step now is to ensure that the Safe Hearts Plan translates into clear and effective measures across the EU with the cooperation between European institutions, Member States, the scientific community, healthcare professionals, patients and civil society."
Parliamentary Stance
Members of the European Parliament (MEPs) involved in the Public Health Committee noted that the inclusion of respiratory health was essential for the plan to be considered "comprehensive." By integrating these disciplines, the Parliament aims to provide a model of care that is more sustainable for aging populations, reducing the strain on emergency services through better chronic disease management.
Implications: A New Era for European Healthcare
The adoption of this report carries profound implications for the future of healthcare delivery in Europe. It mandates that Member States rethink their approach to national health programs.
1. Clinical Practice Transformation
Clinicians can expect to see a move toward "multidisciplinary clinics." The old model, where a patient sees a cardiologist, then a pulmonologist, then a GP, with little communication between them, is increasingly viewed as obsolete. Future healthcare funding will likely be tied to the adoption of "integrated care pathways" where patient data is shared across specialties.
2. Standardization of Screening
The ERS’s ongoing advocacy for respiratory inclusion in standardized health checks is now backed by legislative weight. Member States will likely be encouraged—and potentially incentivized through EU health grants—to include lung function testing in routine cardiovascular check-ups for individuals aged 50 and older or those with high-risk profiles.
3. Policy and Investment
With the Safe Hearts Plan now effectively expanded to include respiratory considerations, funding from the EU4Health program will likely prioritize projects that demonstrate a cross-disease approach. This will provide a significant boost to research initiatives focusing on the molecular and physiological links between heart and lung failure.
4. Patient Empowerment
For the patients, this policy shift represents a move toward more personalized care. By treating the whole patient rather than a specific organ system, the EU aims to improve the quality of life for millions of citizens who currently live with chronic, under-managed conditions.
Conclusion: The Road Ahead
The European Parliament’s decision on 17 September 2026 is a milestone, but it serves only as the foundation. The true test of this policy will be its implementation at the national level. As the European Commission moves to finalize the implementation guidelines for the Safe Hearts Plan, the collaboration between scientific societies like the ERS and policy-makers will be vital.
By embracing a holistic view of human health, the European Union has positioned itself at the forefront of global NCD management. If successfully executed, this integrated approach could serve as a blueprint for healthcare systems worldwide, proving that when it comes to the heart and the lungs, the whole is indeed much greater than the sum of its parts.
For further information on the ongoing advocacy efforts regarding this policy, readers are encouraged to visit the ERS and European Lung Foundation advocacy portal.
